Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry

NCT00986167 is registered in ClinicalTrials.gov with Bayside Health as lead sponsor.

NCT NCT00986167
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00986167 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Determining the Efficacy and Tolerance of Quetiapine Extended Release (XR) for the Management of Psychotic Aggression or Agitation in Adult Acute Psychiatry
Lead sponsor
Bayside Health
Phase
Phase 4
Overall status
Unknown status
Start date
October 31, 2009
Completion date
October 31, 2010
Enrollment
72 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

psychosis, schizophrenia